Skip to content

Prime Medicine PRME Net gains (losses) on investments

Net gains (losses) on investments at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$904K+57.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$16K+101%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$1.71M+98.1%
Opus Genetics logo
Opus GeneticsIRD
$0+100%
Precigen logo
PrecigenPGEN
$0+100%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$85K-22.7%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's net gains (losses) on investments?
Prime Medicine (PRME) reported net gains (losses) on investments of $0 in Q1 2026.
How has Prime Medicine's net gains (losses) on investments changed year-over-year?
Prime Medicine's net gains (losses) on investments increased by 100.0% year-over-year, from -$1.06M to $0.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.